The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://stevecufc705213.creacionblog.com/38705402/retatrutide-vs-tirzepatide-a-comparative-analysis